CMS Wants Faster Drug Prior Authorization Decisions. A New Study Shows Why That Could Matter for Patients

People who are told at the pharmacy that a prescribed drug needs prior authorization already know the problem: even a short delay can mean leaving without the medicine. A new federal proposal could eventually make some of that process faster and more transparent. But nothing changes right away, and the details depend on what kind of coverage you have.

On April 10, 2026, the Centers for Medicare & Medicaid Services proposed extending electronic prior authorization standards and related transparency rules to prescription drugs. If the rule is finalized, key compliance dates would begin on October 1, 2027 for many provisions. The proposal would affect Medicare Advantage organizations, Medicaid and CHIP fee-for-service programs, Medicaid managed care plans, CHIP managed care entities, and Qualified Health Plan issuers on the federally facilitated Marketplace. CMS also proposes adding small-group plans sold through the federally facilitated Small Business Health Options Program to interoperability requirements.

What CMS is proposing

In plain language, CMS wants more of the drug prior authorization process to move through standardized electronic systems instead of phone calls, faxes, and plan-by-plan workarounds.

The proposal would do several things if finalized:

Expand electronic prior authorization standards to drugs.
Require more drug prior authorization information to be available through patient, provider, and payer data-sharing tools known as APIs.
Require public reporting of drug prior authorization metrics, such as approval and denial patterns, with deadlines that vary by payer type.
Require certain plans to give providers a specific reason when a drug prior authorization request is denied.

For patients, the practical goal is easier status tracking and less guesswork. CMS says the API changes would eventually let patients and providers see details such as whether a request is pending, approved, or denied, when that decision happened, when an authorization ends, which drug and dose were approved, and the reason for a denial when applicable.

The proposal also follows a separate voluntary push by insurers to simplify prior authorization, but that earlier effort does not replace federal rulemaking and does not mean this new CMS proposal is already in effect.

Why the timeline is not one simple deadline

This is where the policy gets more complicated. The CMS fact sheet does not set one universal response time for every plan and every type of drug request.

For drugs covered under a medical benefit, such as some drugs given in a clinic or infusion center, CMS proposes that impacted payers add drug coverage and documentation requirements to their prior authorization APIs beginning October 1, 2027.
For drugs covered under a pharmacy benefit, CMS proposes that state Medicaid and CHIP fee-for-service programs, Medicaid and CHIP managed care plans, and federally facilitated Marketplace issuers support specific pharmacy e-prior authorization standards beginning October 1, 2027. CMS says this would align with requirements that already exist for Medicare Part D sponsors.
For decision timeframes, the proposed rule uses different language for different programs. For many Medicaid and CHIP drug requests, the fact sheet points to existing timeframes of no later than 24 hours after receipt for covered outpatient drugs, or existing items-and-services timeframes of 7 days for standard requests and 72 hours for expedited requests. For federally facilitated Marketplace plans, CMS proposes up to 72 hours for standard drug requests and 24 hours for expedited requests.
For public reporting, new drug prior authorization metrics would start in 2028 using data from the 2027 reporting period, with deadlines that also vary by payer type.

That means readers should be careful about headlines that make the proposal sound like one simple nationwide deadline. It is not. It also does not cover every private insurer or every employer plan in the United States.

Why patients should care now

The policy matters because drug prior authorization delays are not just paperwork. A new study published April 17 in JAMA Health Forum gives a clearer picture of what happens after a branded prescription is initially rejected for prior authorization at the pharmacy counter.

The study was a cross-sectional analysis of 2024 retail pharmacy claims. Researchers looked at 205,896 branded medication dispensations that were initially rejected for prior authorization. Only 35% were processed in one day. The rest took longer, with a median processing time of 6 days among those that were not resolved the same day. Overall, 54% were eventually approved.

That is the key point for patients: more than half of these prescriptions were not permanently blocked, but many were still delayed. In real life, that can mean a later treatment start, extra paperwork for the prescriber, repeated calls between the pharmacy and insurer, and uncertainty about whether the prescription will ever be covered.

What the study does and does not prove

The JAMA Health Forum paper is useful, but it is not the final word on all drug coverage problems.

First, it was a cross-sectional claims analysis, not a randomized trial, so it cannot prove that prior authorization directly caused every delay or denial. Second, it focused on branded drugs in the retail pharmacy setting, not generic drugs, not every pharmacy setting, and not other utilization-management tools such as step therapy or quantity limits. Third, the study did not capture everything patients may have done after a denial, such as appealing, paying cash, switching plans, or moving to a different drug. It also could not determine whether each denial was clinically appropriate.

Those limits matter. The study should be read as a careful snapshot of one part of the problem, not proof that every prior authorization denial is wrong or that the CMS proposal would solve all of it.

How common prior authorization already is

Separate data from KFF show how large the prior authorization issue already is in Medicare Advantage. In 2024, Medicare Advantage insurers made nearly 53 million prior authorization determinations and denied 4.1 million requests, or 7.7%. Only 11.5% of denied requests were appealed. But when denials were appealed, 80.7% were partially or fully overturned.

Those KFF figures cover prior authorization across services, not just drugs. Even so, they help explain why patients and clinicians worry about delays. A denial that is later reversed can still mean extra days or weeks without the care a clinician originally ordered.

What the proposal could improve, and what it would not guarantee

If finalized, the CMS rule could make it easier for prescribers to submit the right documentation electronically, easier for patients and providers to see the status of a request, and easier for the public to compare broad prior authorization patterns across some plans.

It would not guarantee immediate approvals. It would not eliminate insurer review. It would not automatically apply to every employer-sponsored plan. And it would not mean patients see relief in 2026, because this is still a proposed rule and the main compliance dates in the fact sheet begin later.

It is also worth noting that Medicare Advantage is part of the broader set of impacted payers in the CMS proposal, but the drug-specific timeline details in the fact sheet are spelled out most clearly for Medicaid, CHIP, and federally facilitated Marketplace coverage. So people in Medicare Advantage should read claims about instant change with caution.

What to ask if your prescription is delayed now

If a drug is held up today, waiting passively can cost time. Ask clear, specific questions:

Why was the prescription delayed: prior authorization, missing documentation, formulary rules, or another coverage issue?
Is this an actual denial, or is the insurer asking for more information?
What exactly does the prescriber need to send?
Can the request be resubmitted, and how soon?
Is an appeal available, and what is the deadline?
How quickly is your plan supposed to respond for this kind of request?
Is there a covered alternative your clinician would consider while the review is pending?

These questions matter because, as the new study shows, a delay can still disrupt treatment even when the prescription is eventually approved.

What this means for readers

The main takeaway is simple: prior authorization delays can matter even when access is not permanently denied. CMS is proposing changes that could make parts of the drug approval process faster and more transparent, especially for people in Medicaid, CHIP, federally facilitated Marketplace plans, and some Medicare Advantage situations. But the proposal is not final, the timelines vary by coverage type, and patients should not expect immediate changes this year.

Sources

This article is for general informational purposes only and is not medical advice. Research findings can be early, limited, or subject to change as new evidence emerges. For personal guidance, diagnosis, or treatment, consult a licensed clinician. For current outbreak or public health guidance, follow your local health department, the CDC, or another relevant public health authority.